The Europe animal health market size was estimated at USD 16.56 billion in 2024 and is projected to reach USD 34.84 billion by 2033, growing at a CAGR of 8.64% from 2025 to 2033. The industry is experiencing growth driven by the rising prevalence of zoonotic and infectious diseases, growth of the companion animal population and pet humanization,advancements in veterinary pharmaceuticals and biologics, and regulatory support and food safety standards.
Increasing outbreaks of zoonotic and infectious diseases have raised concerns across Europe’s livestock and companion animal sectors. According to the French Agricultural Research Centre for International Development CIRAD, France has faced bluetongue virus (BTV) and epizootic hemorrhagic disease (EHD) outbreaks in 2023, with a new BTV strain spreading across Europe in 2024. This growing disease burden drives demand for advanced vaccines, diagnostics, and preventive solutions to ensure biosecurity and herd protection. This leads to greater investment in veterinary pharmaceuticals, surveillance systems, and R&D initiatives. Thus, companies and governments are prioritizing disease control strategies, strengthening the animal health market across Europe.
The rising pet ownership has increased demand for sophisticated veterinary treatment throughout Europe, strengthened by cultural movements toward pet humanization. Pet owners see their pets as part of the family rather than as possessions, thus increasing their expenditure on high-quality food, health programs, and preventative care. According to the Animal Health Europe report, the region places a high priority on caring for companion animals, as evidenced by the 28 billion euros spent on pet food, 25 billion on pet-related goods and services, and 4 billion on animal medications. Increased use of parasiticides, veterinary medications, diagnostic testing, and wellness products is fueled by this trend. Access to high-quality treatment is further supported by the prevalence of pet insurance in countries like the UK, Sweden, and Germany. As a result, the companion animal health sector is becoming one of the most dynamic growth areas, boosting overall market expansion.
Continuous R&D investment in veterinary pharmaceuticals, vaccines, and biologics has enhanced treatment and prevention options for both livestock and companion animals. Disease management is changing as a result of innovations, including next-generation vaccinations, long-acting injectables, and monoclonal antibodies. As per the report of Animal Health Europe, the animal medicines industry invested over USD 649 million in R&D in 2024. Similarly, in 2024, the European Medicines Agency authorized 25 new animal health products for veterinary use. These advancements improve treatment efficacy, reduce resistance issues, and expand preventive healthcare adoption. Companies introducing innovative therapies gain a strong competitive advantage, improving overall herd and pet health outcomes. This accelerates demand for biologics and pharmaceutical products, increasing steady revenue growth and strengthening the innovation pipeline in Europe’s animal health industry.
The European Union upholds stringent laws pertaining to food safety, antimicrobial use, and animal welfare to safeguard both customers and animals. Industry methods have changed as a result of initiatives like the EU's ban on regular antibiotic growth promoters and emphasis on sustainability. These regulations promote the use of probiotics, vaccinations, and sophisticated diagnostics in place of antibiotics. Furthermore, the manufacturers are encouraged to invest in advanced technologies that adhere to the strict safety and efficacy standards of the EU. This regulatory framework supports the long-term growth of the animal health industry in Europe, boosts market expansion, and increases public confidence in the food supply chain.
This product will be delivered within 1-3 business days.
Increasing outbreaks of zoonotic and infectious diseases have raised concerns across Europe’s livestock and companion animal sectors. According to the French Agricultural Research Centre for International Development CIRAD, France has faced bluetongue virus (BTV) and epizootic hemorrhagic disease (EHD) outbreaks in 2023, with a new BTV strain spreading across Europe in 2024. This growing disease burden drives demand for advanced vaccines, diagnostics, and preventive solutions to ensure biosecurity and herd protection. This leads to greater investment in veterinary pharmaceuticals, surveillance systems, and R&D initiatives. Thus, companies and governments are prioritizing disease control strategies, strengthening the animal health market across Europe.
The rising pet ownership has increased demand for sophisticated veterinary treatment throughout Europe, strengthened by cultural movements toward pet humanization. Pet owners see their pets as part of the family rather than as possessions, thus increasing their expenditure on high-quality food, health programs, and preventative care. According to the Animal Health Europe report, the region places a high priority on caring for companion animals, as evidenced by the 28 billion euros spent on pet food, 25 billion on pet-related goods and services, and 4 billion on animal medications. Increased use of parasiticides, veterinary medications, diagnostic testing, and wellness products is fueled by this trend. Access to high-quality treatment is further supported by the prevalence of pet insurance in countries like the UK, Sweden, and Germany. As a result, the companion animal health sector is becoming one of the most dynamic growth areas, boosting overall market expansion.
Continuous R&D investment in veterinary pharmaceuticals, vaccines, and biologics has enhanced treatment and prevention options for both livestock and companion animals. Disease management is changing as a result of innovations, including next-generation vaccinations, long-acting injectables, and monoclonal antibodies. As per the report of Animal Health Europe, the animal medicines industry invested over USD 649 million in R&D in 2024. Similarly, in 2024, the European Medicines Agency authorized 25 new animal health products for veterinary use. These advancements improve treatment efficacy, reduce resistance issues, and expand preventive healthcare adoption. Companies introducing innovative therapies gain a strong competitive advantage, improving overall herd and pet health outcomes. This accelerates demand for biologics and pharmaceutical products, increasing steady revenue growth and strengthening the innovation pipeline in Europe’s animal health industry.
The European Union upholds stringent laws pertaining to food safety, antimicrobial use, and animal welfare to safeguard both customers and animals. Industry methods have changed as a result of initiatives like the EU's ban on regular antibiotic growth promoters and emphasis on sustainability. These regulations promote the use of probiotics, vaccinations, and sophisticated diagnostics in place of antibiotics. Furthermore, the manufacturers are encouraged to invest in advanced technologies that adhere to the strict safety and efficacy standards of the EU. This regulatory framework supports the long-term growth of the animal health industry in Europe, boosts market expansion, and increases public confidence in the food supply chain.
Europe Animal Health Market Report Segmentation
This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the Europe animal health market report based on product, animal and country.Product Outlook (Revenue, USD Million, 2021-2033)
- Biologics
- Pharmaceuticals
- Diagnostics
- Equipment & Disposables
- Medicinal Feed Additives
- Others
Animal Outlook (Revenue, USD Million, 2021-2033)
- Production Animal
- Companion Animal
Country Outlook (Revenue, USD Million, 2021-2033)
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Norway
- Denmark
- Netherlands
- Russia
- Switzerland
- Ireland
- Poland
Why You Should Buy This Report
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
Report Deliverables
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Market Variable Trends & Scope
Chapter 4. Europe Animal Health Market: Animal Estimates & Trend Analysis
List of Tables
List of Figures
Companies Mentioned
The companies profiled in this Europe Animal Health market report include:- Ceva
- Vetoquinol S.A.
- Boehringer Ingelheim International GmbH
- Virbac
- B. Braun Vet Care
- Dechra Pharmaceuticals PLC
- Bimed Inc.
- Zoetic Inc.
- Elanco
- IDEXX Laboratories, Inc.
- MSD Animal Health
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | October 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 16.56 Billion |
| Forecasted Market Value ( USD | $ 34.84 Billion |
| Compound Annual Growth Rate | 8.6% |
| Regions Covered | Europe |
| No. of Companies Mentioned | 12 |
